Does George Soros Think Biotech's Bull Run Is Finally Coming to an End?
George Budwell, The Motley Fool - Motley Fool - Mon Dec 15, 6:45AM CST
To say that biotech stocks have performed well as a group over the last two years is an understatement; they have absolutely crushed the broader markets. For example, the iShares Nasdaq Biotech Index has more than tripled the performance of the ...
SRPT: 12.60 (-0.40), IBB: 293.67 (-3.99), ARIA: 6.08 (-0.02), CELG: 110.09 (-1.79)
SmarTrend Watching for Potential Rebound in Shares of Ariad Pharmaceuticals After 7.76% Loss
Comtex SmarTrend(R) - Thu Dec 11, 4:40PM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) traded in a range yesterday that spanned from a low of $6.34 to a high of $6.88. Yesterday, the shares fell 7.8%, which took the trading range below the 3-day low of $6.80 on volume of 13.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ARIA: 6.08 (-0.02)
Energy Stocks Pare Gains as Crude Oil Closes Below $60 For First Time in Five Years
at The Street - Thu Dec 11, 1:52PM CST
Energy stocks are leading the markets higher, a day after they sparked a selloff.
SPLS: 17.25 (+0.40), DAL: 45.38 (-2.42), XOM: 86.41 (-0.49), COP: 63.22 (+1.53), LLY: 69.26 (-0.41), LULU: 52.50 (-1.37), LUV: 39.58 (-2.00), URBN: 32.63 (+0.16), EBAY: 55.94 (+0.50), AAL: 47.96 (-2.88), ODP: 7.92 (+0.08), ARIA: 6.08 (-0.02), CVX: 101.70 (+0.84), WAG: 72.39 (-1.05), XLE: 74.01 (+0.65)
Nasdaq stocks posting largest percentage decreases
AP - Thu Dec 11, 12:19PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
AMBA: 45.78 (-0.35), LNCO: 10.87 (+1.71), MCEP: 6.16 (+0.66), LAKE: 9.19 (-0.46), CLDN: 17.76 (+0.03), BRID: 7.54 (+0.04), ARIA: 6.08 (-0.02), LINE: 12.54 (+2.71), MIND: 5.82 (+0.13), DGLY: 14.38 (+0.34), ALLT: 8.48 (-0.04), ROSE: 18.39 (+1.18)
Ariad slumps after analyst downgrade
Seeking Alpha - at Seeking Alpha - Thu Dec 11, 9:25AM CST
IBB: 293.67 (-3.99), ARIA: 6.08 (-0.02)
Will Ariad Pharmaceuticals (ARIA) Stock be Affected Today by This Analyst Action?
at The Street - Thu Dec 11, 8:14AM CST
Shares of Ariad Pharmaceuticals (ARIA) are down after Credit Suisse downgraded the global oncology company to 'underperform' from 'neutral' and lowered its price target to $6 from $8.
ARIA: 6.08 (-0.02)
Downgrade Alert for Ariad Pharmaceuticals (ARIA)
Comtex SmarTrend(R) - Thu Dec 11, 6:54AM CST
Ariad Pharmaceuticals (NASDAQ:ARIA) was downgraded from Neutral to Underperform at Credit Suisse today. The stock closed yesterday at $7.02 on volume of 4.6 million shares, below average daily volume of 6.3 million. In the past 52 weeks, Ariad Pharmaceuticals share prices have been bracketed by a low of $3.80 and a high of $9.83 and closed yesterday at $7.02, 85% above that low price. Over the last five market days, the 200-day moving average (MA) has gone down 0.3% while the 50-day MA has advanced 1.5%.
ARIA: 6.08 (-0.02)
Uptrend Call Working As Ariad Pharmaceuticals Stock Rises 22.6% (ARIA)
Comtex SmarTrend(R) - Tue Dec 09, 5:08PM CST
SmarTrend identified an Uptrend for Ariad Pharmaceuticals (NASDAQ:ARIA) on October 29th, 2014 at $5.92. In approximately 1 month, Ariad Pharmaceuticals has returned 22.57% as of today's recent price of $7.25.
ARIA: 6.08 (-0.02)
Long-term follow up data for Iclusig positive
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 9:54AM CST
ARIA: 6.08 (-0.02)
ARIAD Announces Follow-up Data from Phase 1 and PACE Trials of Ponatinib in Patients with T315I Mutation in Chronic Myeloid Leukemia
Business Wire - Tue Dec 09, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced safety and efficacy follow-up data on Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in patients with a baseline T315I mutation from its Phase 1 and Phase 2 PACE trials in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
ARIA: 6.08 (-0.02)
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib in Chronic-Phase Chronic Myeloid Leukemia from Phase 1 Clinical Trial
Business Wire - Tue Dec 09, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term follow up data from the Phase 1 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of four years in chronic phase CML (CP-CML) patients, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options and that responses have been maintained in CP-CML patients (n=43) with 72 percent having a major cytogenetic response (MCyR), 65 percent having a complete cytogenetic response (CCyR) and 56 percent having a major molecular response (MMR). Long-term safety data show that careful benefit-risk evaluations should guide decisions to use and maintain ponatinib therapy, particularly in patients who may be at increased risk for arterial thrombotic events.
ARIA: 6.08 (-0.02)
ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial
Business Wire - Mon Dec 08, 6:35AM CST
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced long-term follow up from its pivotal Phase 2 trial of Iclusig(R) (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study now shows that with a median follow-up of approximately 3 years for chronic-phase CML (CP-CML) patients in the trial, Iclusig continues to demonstrate anti-leukemic activity in patients with limited treatment options. Deep and durable responses have been maintained in CP-CML patients with 83 percent of CP-CML patients who achieved a response, estimated to remain in major cytogenetic response (MCyR) at three years.
ARIA: 6.08 (-0.02)
Why Ariad Pharmaceuticals, Inc. Stock Catapulted 19% Higher in November
Sean Williams, The Motley Fool - Motley Fool - Fri Dec 05, 7:36AM CST
ARIA data by YCharts What: Shares of Ariad Pharmaceuticals , a biopharmaceutical company focused on developing therapies to treat cancer, surged by 19% in November according to data from S&P Capital IQ after reporting market-topping...
ARIA: 6.08 (-0.02)
ARIAD Pharmaceuticals (ARIA) Is Strong On High Volume Today
at The Street - Tue Dec 02, 9:00AM CST
Trade-Ideas LLC identified ARIAD Pharmaceuticals (ARIA) as a strong on high relative volume candidate
ARIA: 6.08 (-0.02)
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 4.00 (-0.08), BIB: 118.31 (-2.94), INCY: 71.62 (-0.52), PFE: 30.67 (-0.19), IBB: 293.67 (-3.99), DRGS: 52.00 (unch), BIND: 5.56 (+0.01), BMY: 57.69 (-0.86), GSK: 41.92 (+0.62), ONTY: 1.76 (-0.14), ECYT: 5.88 (-0.16), BIS: 50.05 (+1.20), CLVS: 53.28 (+0.09), AZN: 69.56 (-0.18), MRK: 56.80 (-0.15), ARIA: 6.08 (-0.02), IRY: 46.98 (+0.45), IXJ: 99.16 (-0.64), FPRX: 21.92 (+0.07)
Most active Nasdaq-traded stocks
AP - Tue Nov 25, 5:58PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
MU: 32.92 (-0.43), GILD: 100.46 (-2.70), FB: 74.69 (-2.30), CMCSK: 54.53 (-0.18), ARIA: 6.08 (-0.02), ARCP: 7.70 (-0.53), MSFT: 45.16 (-1.51), INTC: 35.56 (-0.36), CMCSA: 54.81 (-0.13), AAPL: 106.75 (-1.47), CSCO: 26.58 (-0.10)
Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 25, 8:25AM CST
Ariad Pharmaceuticals (ARIA) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
LCI: 42.70 (-1.35), VRX: 136.92 (-1.24), SCMP: 12.89 (+0.23), ARIA: 6.08 (-0.02)